Latest Breaking News On - அலெக்சாண்டர் மருதாணி - Page 1 : vimarsana.com
Frisbie Memorial Hospital welcomes new Advanced Orthopedics practice
seacoastonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seacoastonline.com Daily Mail and Mail on Sunday newspapers.
Over the past decade, the European Union has been tightening its regulatory grip on neonicotinoid insecticides in response to an increasingly strong body of research suggesting they are lethal for pollinators such as bees.
But four neonicotinoid insecticides the EU has banned are still being used in the region thanks to a legal loophole.
In May 2013, the European Commission (the EU’s executive branch) banned the use of three neonicotinoids imidacloprid, thiamethoxam and clothianidin on flowering crops attractive to pollinators as well as cereals. In May 2018, it went further and banned all outdoor uses of the trio, and in February 2020, it decided not to renew the approval of a fourth neonicotinoid called thiacloprid, resulting in its
CONTENT: Press Release
MONHEIM, Germany, February 15, 2021 /3BL Media/ – As part of the company’s Future of Farming Dialogue virtual event series, Bob Reiter, Head of Research and Development at the Crop Science division of Bayer, will highlight the interconnectivity between scientific experts inside and outside of the company’s own network of R&D resources, their importance to innovation, and the next solutions to advance the future of agriculture. Reiter will join with CEOs from Pairwise, Rantizo and Oerth Bio during the global virtual event Open Innovation: How Collaboration Unlocks a Sustainable Future on February 15, 2021 (9:30am CST/4:30pm CET).
“As a leader in this space, Bayer is committed to transforming agriculture through our open innovation model,” said Reiter. “This R&D strategy allows us to join forces with partners of all sizes – from start-ups and scale-ups to academic institutions and established companies – to actively seek new creative ideas acr
Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities
Top industry leaders and venture firms unite behind Ukko s efforts to eliminate the world s most prevalent food allergies and sensitivities, including peanuts and gluten
News provided by
Share this article
Share this article
PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 /PRNewswire/ Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, today announced $40 million in new Series B funding. Ukko harnesses artificial intelligence (AI) and protein engineering to develop healthier food and therapies for food allergies. The new funding will allow Ukko to enter clinical trials with its investigational therapeutic for peanut allergy. It will also accelerate development of Ukko s gluten that is designed for people with celiac and other gluten sensitivities. The round was led by Leaps by Bayer – the impact investm
vimarsana © 2020. All Rights Reserved.